本帖最后由 老马 于 2012-1-13 21:20 编辑
0 m5 n# G% P, |. H$ _/ N. A" u U( Z
爱必妥和阿瓦斯丁的比较/ u# f" b% ~& X/ k, o0 F5 ]
1 q- X4 p* ?. z/ U; q) j& lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/# |; x4 D' i" X8 ]/ b4 P
# h' E' K) f, v2 X
+ t0 [) T& U4 X1 L2 Q
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 e/ J7 b8 X. `( |& J+ m5 u8 N' A
==================================================
' y; T7 e9 p, T3 h i- i4 Y0 V0 lOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). a- h8 d6 Q6 M1 q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.$ T& V# h. h$ Q& L( d" {9 Y( i
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 \$ o! [+ f0 A: M
|